Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2009 | 09-2009 | 06-2009 | 03-2009 | 12-2008 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,272,958 | 1,024,599 | 1,040,874 | 1,663,646 | 1,459,302 |
| Marketable Securities | 384,017 | 330,713 | 203,394 | 396,648 | 330,760 |
| Receivables | 1,389,534 | 1,339,165 | 1,242,899 | 1,068,000 | 1,023,397 |
| Inventories | 1,051,771 | 1,017,827 | 969,971 | 936,727 | 927,868 |
| Income taxes - deferred | 295,080 | 192,701 | 185,439 | 135,612 | 140,882 |
| Other current assets | 66,891 | 59,714 | 78,127 | 164,929 | 126,066 |
| TOTAL | $4,812,558 | $4,297,610 | $4,001,307 | $4,615,915 | $4,278,408 |
| Non-Current Assets | |||||
| PPE Net | 699,970 | 701,371 | 697,426 | 679,437 | 528,799 |
| Investments And Advances | 2,247,871 | 1,936,818 | 1,654,178 | 1,548,595 | 1,449,577 |
| Intangibles | 1,524,777 | 1,555,602 | 1,570,790 | 0 | 123,008 |
| Other Non-Current Assets | 413,383 | 445,579 | 463,391 | 675,967 | 557,039 |
| TOTAL | $4,886,001 | $4,639,370 | $4,385,785 | $2,903,999 | $2,658,423 |
| Total Assets | $9,698,559 | $8,936,980 | $8,387,092 | $7,519,914 | $6,936,831 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 205,613 | 405,622 | 5,613 | 5,631 |
| Accounts payable and accrued liabilities | 810,544 | 742,684 | 649,999 | 578,362 | 601,200 |
| Accrued Expenses | 381,141 | 356,398 | 311,211 | 277,500 | 280,779 |
| TOTAL | $1,871,631 | $1,889,249 | $1,777,882 | $1,261,797 | $1,220,992 |
| Non-Current Liabilities | |||||
| Long Term Debt | 35,918 | 42,363 | 50,084 | 21,095 | 21,462 |
| Deferred Revenues | 122,721 | 49,362 | 46,345 | 48,300 | 42,963 |
| Other Non-Current Liabilities | 1,245,645 | 1,211,199 | 1,193,993 | 1,170,990 | 1,156,982 |
| TOTAL | $1,321,770 | $1,295,574 | $1,295,241 | $1,240,834 | $1,250,256 |
| Total Liabilities | $3,193,401 | $3,184,823 | $3,073,123 | $2,502,631 | $2,471,248 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,806,758 | 1,799,850 | 1,808,523 | 1,812,791 | 1,821,909 |
| Common Shares | 900 | 902 | 905 | 906 | 910 |
| Retained earnings | 1,995,272 | 1,420,613 | 1,019,839 | 672,956 | 300,314 |
| Other shareholders' equity | 132,335 | 66,420 | 147,411 | 324,838 | 234,250 |
| TOTAL | $6,505,158 | $5,752,157 | $5,313,969 | $5,017,283 | $4,465,583 |
| Total Liabilities And Equity | $9,698,559 | $8,936,980 | $8,387,092 | $7,519,914 | $6,936,831 |